Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1976 1
1979 1
1980 1
1982 1
1986 1
1988 1
1991 1
1993 1
1996 1
1997 3
1998 1
2000 1
2001 1
2002 1
2003 3
2006 1
2007 2
2008 1
2009 3
2010 2
2011 4
2012 6
2013 8
2014 6
2015 6
2016 4
2017 4
2018 5
2019 6
2020 6
2021 12
2022 7
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Primary Myelofibrosis"
Page 1
JAK-mutant myeloproliferative neoplasms.
Levine RL. Levine RL. Curr Top Microbiol Immunol. 2012;355:119-33. doi: 10.1007/82_2011_170. Curr Top Microbiol Immunol. 2012. PMID: 21823028 Review.
Although the Janus family of kinases (JAK1, JAK2, JAK3, and TYK2) has been extensively characterized and investigated, the role of Janus kinase activation in the pathogenesis and therapy of human malignancies was not fully appreciated until recently when multiple studies identifi …
Although the Janus family of kinases (JAK1, JAK2, JAK3, and TYK2) has been extensively characterized and investigated, the role of Janus kin …
Improving allogeneic stem cell transplantation in myelofibrosis.
Gagelmann N, Kröger N. Gagelmann N, et al. Int J Hematol. 2022 May;115(5):619-625. doi: 10.1007/s12185-022-03340-w. Epub 2022 Apr 13. Int J Hematol. 2022. PMID: 35419771 Review.
In this review, we will outline dimensions in which outcome of patients with myelofibrosis undergoing curative treatment can be optimized: patient selection, transplant procedure, and posttransplant prevention or treatment of relapse. For patient selection, fortunately, as …
In this review, we will outline dimensions in which outcome of patients with myelofibrosis undergoing curative treatment can be optim …
Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR, Laffan M. Arachchillage DR, et al. Semin Thromb Hemost. 2019 Sep;45(6):604-611. doi: 10.1055/s-0039-1693477. Epub 2019 Aug 5. Semin Thromb Hemost. 2019. PMID: 31382304 Free article. Review.
Chronic myeloproliferative neoplasms (MPN) are characterized by clonal expansion of an abnormal hematopoietic stem/progenitor cell and include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Venous thrombosis, often at unusua …
Chronic myeloproliferative neoplasms (MPN) are characterized by clonal expansion of an abnormal hematopoietic stem/progenitor cell and inclu …
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation.
Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol F, Wolschke C, Robin M, Heuser M, Rubio MT, Maciejewski JP, Reinhardt HC, Scott BL, Kröger N. Gagelmann N, et al. Blood. 2023 Jun 8;141(23):2901-2911. doi: 10.1182/blood.2023019630. Blood. 2023. PMID: 36940410 Free PMC article.
TP53 mutations (TP53MTs) have been associated with poor outcomes in various hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis undergoing hematopoietic stem cell transplantation (HSCT). ...In summary, multihit TP53MT represents a …
TP53 mutations (TP53MTs) have been associated with poor outcomes in various hematologic malignancies, but no data exist regarding its role i …
Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
Savani M, Dulery R, Bazarbachi AH, Mohty R, Brissot E, Malard F, Bazarbachi A, Nagler A, Mohty M. Savani M, et al. Br J Haematol. 2021 Nov;195(4):495-506. doi: 10.1111/bjh.17469. Epub 2021 Apr 21. Br J Haematol. 2021. PMID: 33881169 Review.
Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-established molecular drivers. ...With a disease course that varies from indolent to highly progressive, we are now able to stratify risk of mortality through various t …
Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes and well-established molecular driver …
Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.
Tamari R, Castro-Malaspina H. Tamari R, et al. Curr Opin Hematol. 2015 Mar;22(2):184-90. doi: 10.1097/MOH.0000000000000121. Curr Opin Hematol. 2015. PMID: 25635756 Review.
We reviewed here the recent published data and outline the criteria to select patients with myelofibrosis who can benefit the most from this curative treatment. RECENT FINDINGS: Data regarding mutations in myelofibrosis have been useful to better define the prognosi …
We reviewed here the recent published data and outline the criteria to select patients with myelofibrosis who can benefit the most fr …
Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol.
Raiola AM, Angelucci E, Sica S, Bacigalupo A. Raiola AM, et al. Blood Rev. 2023 Nov;62:101031. doi: 10.1016/j.blre.2022.101031. Epub 2022 Nov 11. Blood Rev. 2023. PMID: 36435691 Review.
The diagnosis was acute myeloid leukemia (AML) (n = 251), acute lymphoblastic leukemia (ALL)(n = 107), myelodysplastic syndrome and myelofibrosis (MDS + MF) (n = 125) and chronic lymphoproliferative disorders (n = 151). ...Graft versus host disease (GvHD) prophylaxis was i …
The diagnosis was acute myeloid leukemia (AML) (n = 251), acute lymphoblastic leukemia (ALL)(n = 107), myelodysplastic syndrome and myelo …
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Am J Hematol. 2015. PMID: 25611051 Free article. Review.
Differential diagnosis in ET includes reactive thrombocytosis, chronic myeloid leukemia, and prefibrotic myelofibrosis. Janus kinase 2 (JAK2), calreticulin (CALR), or myeloproliferative leukemia virus oncogene (MPL) mutations occur in approximately 55%, 25%, and 3% of ET p …
Differential diagnosis in ET includes reactive thrombocytosis, chronic myeloid leukemia, and prefibrotic myelofibrosis. Janus kinase …
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A, Gerds AT. Nazha A, et al. Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14. Oncologist. 2016. PMID: 26975864 Free PMC article. Review.
The goals of therapy in patients with polycythemia vera (PV) are to improve disease-related symptoms, prevent the incidence or recurrence of thrombosis, and possibly delay or prevent the transformation into myelofibrosis or acute myeloid leukemia (AML). ...More impo …
The goals of therapy in patients with polycythemia vera (PV) are to improve disease-related symptoms, prevent the incidence or recurrence …
98 results